Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Figure 2
Tregs inhibit CTL function in vitro. (a) Activated splenocytes from DC-treated mice were cocultured with CD4+CD25+Foxp3+ cells (purified from tumor-bearing mice) in different ratios. The percentage of intracellular IFN- of CD8+ cells was measured using flow cytometry. And (b) the percentage of intracellular IFN- and granzyme B expression was measured using FACS. A reduction in the IFN- and granzyme B expression was found especially in those fractions where increasing doses of Treg were added to the CD8+ T cells.
